Neuraxis declares common-stock dividend for Series B preferred, ~81,339 shares to be issued
Neuraxis declared a stock dividend for its Series B Preferred, converting accrued Q3 2026 dividends into common shares. Approximately 81,339 common shares will be issued, with fractional shares paid in cash at $2.38 per share. The dividend is payable on October 30, 2026, to holders of record as of October 26, 2026, according to the company.
How this was made
The 30-second read
Why it matters
The small‑scale stock dividend adds ~81k shares, causing modest dilution and a likely slight price dip.
Market read
Primary corporate action for a micro‑cap; limited trading relevance beyond NRXS shareholders.
What to watch
Potential tax implications for shareholders receiving cash for fractional shares.
Background
Neuraxis filed an 8‑K on Oct 14, 2026 announcing the conversion of accrued Series B preferred dividends into common stock.
Ticker impact
Neuraxis announced a common‑stock dividend converting accrued Series B preferred dividends into approximately 81,339 new common shares.
likely slight pressure as the market prices in the dilution from the new shares
The filing details a small number of shares (81k) relative to the float, so impact is limited but measurable.
Market effects
Minimal; the dividend conversion does not materially affect the broader biotech sector.
Limited to US micro‑cap investors tracking NRXS.
None
Counterpoint
Some investors may view the dividend conversion as a positive sign of cash flow stability despite dilution.
Key entities
- CompanyNeuraxis, Inc.
Biotech firm issuing the dividend conversion.